H+ Transporting Two Sector ATPase - Pipeline Review, H1 2020
H+ Transporting Two Sector ATPase - Pipeline Review, H1 2020
SUMMARY
According to the recently published report 'H+ Transporting Two Sector ATPase - Pipeline Review, H1 2020'; H+ Transporting Two Sector ATPase (F1F0 ATP Synthase or ATP Synthase or Mitochondrial ATPase or Bacterial Ca2+/Mg2+ ATPase or EC 7.1.2.2) pipeline Target constitutes close to 5 molecules. Out of which approximately 3 molecules are developed by companies and remaining by the universities/institutes.
H+ Transporting Two Sector ATPase (F1F0 ATP Synthase or ATP Synthase or Mitochondrial ATPase or Bacterial Ca2+/Mg2+ ATPase or EC 7.1.2.2) - ATP synthase (EC 3.6.3.14) is an important enzyme that creates the energy storage molecule adenosine triphosphate (ATP). The majority of cellular energy in the form of adenosine triphosphate (ATP) is synthesized by the ubiquitous F1F0 ATP synthase. Power for ATP synthesis derives from an electrochemical proton (or Na+) gradient, which drives rotation of membranous F0 motor components.
The report 'H+ Transporting Two Sector ATPase - Pipeline Review, H1 2020' outlays comprehensive information on the H+ Transporting Two Sector ATPase (F1F0 ATP Synthase or ATP Synthase or Mitochondrial ATPase or Bacterial Ca2+/Mg2+ ATPase or EC 7.1.2.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in H+ Transporting Two Sector ATPase (F1F0 ATP Synthase or ATP Synthase or Mitochondrial ATPase or Bacterial Ca2+/Mg2+ ATPase or EC 7.1.2.2) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase II and Phase I stages are 1, 1 and 1 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Infectious Disease and Immunology which include indications Tuberculosis, Leprosy, Plaque Psoriasis (Psoriasis Vulgaris) and Pulmonary Tuberculosis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
According to the recently published report 'H+ Transporting Two Sector ATPase - Pipeline Review, H1 2020'; H+ Transporting Two Sector ATPase (F1F0 ATP Synthase or ATP Synthase or Mitochondrial ATPase or Bacterial Ca2+/Mg2+ ATPase or EC 7.1.2.2) pipeline Target constitutes close to 5 molecules. Out of which approximately 3 molecules are developed by companies and remaining by the universities/institutes.
H+ Transporting Two Sector ATPase (F1F0 ATP Synthase or ATP Synthase or Mitochondrial ATPase or Bacterial Ca2+/Mg2+ ATPase or EC 7.1.2.2) - ATP synthase (EC 3.6.3.14) is an important enzyme that creates the energy storage molecule adenosine triphosphate (ATP). The majority of cellular energy in the form of adenosine triphosphate (ATP) is synthesized by the ubiquitous F1F0 ATP synthase. Power for ATP synthesis derives from an electrochemical proton (or Na+) gradient, which drives rotation of membranous F0 motor components.
The report 'H+ Transporting Two Sector ATPase - Pipeline Review, H1 2020' outlays comprehensive information on the H+ Transporting Two Sector ATPase (F1F0 ATP Synthase or ATP Synthase or Mitochondrial ATPase or Bacterial Ca2+/Mg2+ ATPase or EC 7.1.2.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in H+ Transporting Two Sector ATPase (F1F0 ATP Synthase or ATP Synthase or Mitochondrial ATPase or Bacterial Ca2+/Mg2+ ATPase or EC 7.1.2.2) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase II and Phase I stages are 1, 1 and 1 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively. Report covers products from therapy areas Infectious Disease and Immunology which include indications Tuberculosis, Leprosy, Plaque Psoriasis (Psoriasis Vulgaris) and Pulmonary Tuberculosis.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for H+ Transporting Two Sector ATPase (F1F0 ATP Synthase or ATP Synthase or Mitochondrial ATPase or Bacterial Ca2+/Mg2+ ATPase or EC 3.6.3.14)
- The report reviews H+ Transporting Two Sector ATPase (F1F0 ATP Synthase or ATP Synthase or Mitochondrial ATPase or Bacterial Ca2+/Mg2+ ATPase or EC 3.6.3.14) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in H+ Transporting Two Sector ATPase (F1F0 ATP Synthase or ATP Synthase or Mitochondrial ATPase or Bacterial Ca2+/Mg2+ ATPase or EC 3.6.3.14) targeted therapeutics and enlists all their major and minor projects
- The report assesses H+ Transporting Two Sector ATPase (F1F0 ATP Synthase or ATP Synthase or Mitochondrial ATPase or Bacterial Ca2+/Mg2+ ATPase or EC 3.6.3.14) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to H+ Transporting Two Sector ATPase (F1F0 ATP Synthase or ATP Synthase or Mitochondrial ATPase or Bacterial Ca2+/Mg2+ ATPase or EC 3.6.3.14) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for H+ Transporting Two Sector ATPase (F1F0 ATP Synthase or ATP Synthase or Mitochondrial ATPase or Bacterial Ca2+/Mg2+ ATPase or EC 3.6.3.14)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding H+ Transporting Two Sector ATPase (F1F0 ATP Synthase or ATP Synthase or Mitochondrial ATPase or Bacterial Ca2+/Mg2+ ATPase or EC 3.6.3.14) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
H+ Transporting Two Sector ATPase (F1F0 ATP Synthase or ATP Synthase or Mitochondrial ATPase or Bacterial Ca2+/Mg2+ ATPase or EC 7.1.2.2) - Overview
H+ Transporting Two Sector ATPase (F1F0 ATP Synthase or ATP Synthase or Mitochondrial ATPase or Bacterial Ca2+/Mg2+ ATPase or EC 7.1.2.2) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
H+ Transporting Two Sector ATPase (F1F0 ATP Synthase or ATP Synthase or Mitochondrial ATPase or Bacterial Ca2+/Mg2+ ATPase or EC 7.1.2.2) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
H+ Transporting Two Sector ATPase (F1F0 ATP Synthase or ATP Synthase or Mitochondrial ATPase or Bacterial Ca2+/Mg2+ ATPase or EC 7.1.2.2) - Companies Involved in Therapeutics Development
Johnson & Johnson
Lycera Corp
Shanghai Jiatan Pharmaceutical Technology Co Ltd
H+ Transporting Two Sector ATPase (F1F0 ATP Synthase or ATP Synthase or Mitochondrial ATPase or Bacterial Ca2+/Mg2+ ATPase or EC 7.1.2.2) - Drug Profiles
bedaquiline fumarate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LYC-30937 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit F0F1-ATP Synthase for Tuberculosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit ATP Synthase for Tuberculosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
WX-081 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
H+ Transporting Two Sector ATPase (F1F0 ATP Synthase or ATP Synthase or Mitochondrial ATPase or Bacterial Ca2+/Mg2+ ATPase or EC 7.1.2.2) - Dormant Products
H+ Transporting Two Sector ATPase (F1F0 ATP Synthase or ATP Synthase or Mitochondrial ATPase or Bacterial Ca2+/Mg2+ ATPase or EC 7.1.2.2) - Product Development Milestones
Featured News & Press Releases
Dec 16, 2019: World Health Organization recommends the use of Bedaquiline-containing treatment regimens for all drug-resistant Tuberculosis patients
Dec 12, 2019: CHMP recommended extension of indication for Sirturo
Aug 09, 2019: Janssen Announces U.S. FDA Accelerated Approval for SIRTURO (bedaquiline) as Part of Combination Therapy to Treat Adolescents with Pulmonary Multidrug-Resistant Tuberculosis
Jun 28, 2019: New method reveals how well TB antibiotics reach their targets
Apr 25, 2019: MSF: Johnson & Johnson should make TB drug available for all at $1/day
Aug 17, 2018: World Health Organization recommends the use of bedaquiline in all conventional multidrug-resistant tuberculosis treatment regimens
Jul 04, 2018: New drugs to treat top infectious disease killer a possibility with Otago discovery
Apr 25, 2017: Janssen Files NDA in Japan for Multidrug-Resistant Tuberculosis Drug Bedaquiline Fumarate
Dec 07, 2016: Lycera Announces Initiation of Phase 2 UPRISE Clinical Trial of LYC-30937-EC for Patients with Moderate Psoriasis
Dec 01, 2016: China Food And Drug Administration Approves Sirturo (Bedaquiline) For Patients With Pulmonary Multi-Drug Resistant Tuberculosis (MDR-TB)
Aug 22, 2016: Lycera Announces Initiation of Phase 2 Clinical Trial of LYC-30937-EC in Patients with Ulcerative Colitis
Jun 06, 2016: Speeding up drug discovery to fight tuberculosis
Mar 18, 2016: Lycera Announces Presentation of Positive Preclinical Results for Lead Candidate LYC-30937 at the 11th Congress of the European Crohn’s and Colitis Organization (ECCO)
Aug 24, 2015: Janssen’s SIRTURO to be commissioned by NHS England for the treatment of multi-drug resistant tuberculosis
Apr 30, 2015: Lycera Initiates Phase 1 Clinical Trial of LYC-30937, a First-In-Class ATPase Modulator for Inflammatory Bowel Disease
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
H+ Transporting Two Sector ATPase (F1F0 ATP Synthase or ATP Synthase or Mitochondrial ATPase or Bacterial Ca2+/Mg2+ ATPase or EC 7.1.2.2) - Overview
H+ Transporting Two Sector ATPase (F1F0 ATP Synthase or ATP Synthase or Mitochondrial ATPase or Bacterial Ca2+/Mg2+ ATPase or EC 7.1.2.2) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
H+ Transporting Two Sector ATPase (F1F0 ATP Synthase or ATP Synthase or Mitochondrial ATPase or Bacterial Ca2+/Mg2+ ATPase or EC 7.1.2.2) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
H+ Transporting Two Sector ATPase (F1F0 ATP Synthase or ATP Synthase or Mitochondrial ATPase or Bacterial Ca2+/Mg2+ ATPase or EC 7.1.2.2) - Companies Involved in Therapeutics Development
Johnson & Johnson
Lycera Corp
Shanghai Jiatan Pharmaceutical Technology Co Ltd
H+ Transporting Two Sector ATPase (F1F0 ATP Synthase or ATP Synthase or Mitochondrial ATPase or Bacterial Ca2+/Mg2+ ATPase or EC 7.1.2.2) - Drug Profiles
bedaquiline fumarate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LYC-30937 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit F0F1-ATP Synthase for Tuberculosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit ATP Synthase for Tuberculosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
WX-081 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
H+ Transporting Two Sector ATPase (F1F0 ATP Synthase or ATP Synthase or Mitochondrial ATPase or Bacterial Ca2+/Mg2+ ATPase or EC 7.1.2.2) - Dormant Products
H+ Transporting Two Sector ATPase (F1F0 ATP Synthase or ATP Synthase or Mitochondrial ATPase or Bacterial Ca2+/Mg2+ ATPase or EC 7.1.2.2) - Product Development Milestones
Featured News & Press Releases
Dec 16, 2019: World Health Organization recommends the use of Bedaquiline-containing treatment regimens for all drug-resistant Tuberculosis patients
Dec 12, 2019: CHMP recommended extension of indication for Sirturo
Aug 09, 2019: Janssen Announces U.S. FDA Accelerated Approval for SIRTURO (bedaquiline) as Part of Combination Therapy to Treat Adolescents with Pulmonary Multidrug-Resistant Tuberculosis
Jun 28, 2019: New method reveals how well TB antibiotics reach their targets
Apr 25, 2019: MSF: Johnson & Johnson should make TB drug available for all at $1/day
Aug 17, 2018: World Health Organization recommends the use of bedaquiline in all conventional multidrug-resistant tuberculosis treatment regimens
Jul 04, 2018: New drugs to treat top infectious disease killer a possibility with Otago discovery
Apr 25, 2017: Janssen Files NDA in Japan for Multidrug-Resistant Tuberculosis Drug Bedaquiline Fumarate
Dec 07, 2016: Lycera Announces Initiation of Phase 2 UPRISE Clinical Trial of LYC-30937-EC for Patients with Moderate Psoriasis
Dec 01, 2016: China Food And Drug Administration Approves Sirturo (Bedaquiline) For Patients With Pulmonary Multi-Drug Resistant Tuberculosis (MDR-TB)
Aug 22, 2016: Lycera Announces Initiation of Phase 2 Clinical Trial of LYC-30937-EC in Patients with Ulcerative Colitis
Jun 06, 2016: Speeding up drug discovery to fight tuberculosis
Mar 18, 2016: Lycera Announces Presentation of Positive Preclinical Results for Lead Candidate LYC-30937 at the 11th Congress of the European Crohn’s and Colitis Organization (ECCO)
Aug 24, 2015: Janssen’s SIRTURO to be commissioned by NHS England for the treatment of multi-drug resistant tuberculosis
Apr 30, 2015: Lycera Initiates Phase 1 Clinical Trial of LYC-30937, a First-In-Class ATPase Modulator for Inflammatory Bowel Disease
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Indication, H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Number of Products under Investigation by Universities/Institutes, H1 2020
Products under Investigation by Universities/Institutes, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Pipeline by Johnson & Johnson, H1 2020
Pipeline by Lycera Corp, H1 2020
Pipeline by Shanghai Jiatan Pharmaceutical Technology Co Ltd, H1 2020
Dormant Projects, H1 2020
Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Indication, H1 2020
Number of Products under Development by Companies, H1 2020
Products under Development by Companies, H1 2020
Number of Products under Investigation by Universities/Institutes, H1 2020
Products under Investigation by Universities/Institutes, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Pipeline by Johnson & Johnson, H1 2020
Pipeline by Lycera Corp, H1 2020
Pipeline by Shanghai Jiatan Pharmaceutical Technology Co Ltd, H1 2020
Dormant Projects, H1 2020
LIST OF FIGURES
Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Top 10 Indications, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
COMPANIES MENTIONED
Johnson & Johnson
Lycera Corp
Shanghai Jiatan Pharmaceutical Technology Co Ltd
Number of Products under Development by Stage of Development, H1 2020
Number of Products under Development by Therapy Areas, H1 2020
Number of Products under Development by Top 10 Indications, H1 2020
Number of Products by Stage and Mechanism of Actions, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
COMPANIES MENTIONED
Johnson & Johnson
Lycera Corp
Shanghai Jiatan Pharmaceutical Technology Co Ltd
